ASSURE WCD Clinical Evaluation for Sudden Cardiac Arrest

This study, called ACE-PAS, is looking at how well the ASSURE wearable cardioverter defibrillator (WCD) works in real-world settings for people at risk of sudden cardiac arrest. The WCD is a device worn on the body that can deliver an electrical shock (defibrillation) to restart the heart if it stops suddenly. Researchers want to see how often the device successfully delivers a shock when needed (overall shock conversion rate) and how often it delivers a shock when it's not needed (inappropriate shocks). You can join if you are an adult who has been prescribed the ASSURE WCD and agree to participate in the ASSURE Patient Registry. The study is currently collecting information from over 5,000 participants, but its current recruitment status is unclear.

Study design
This is an observational study collecting real-world data from over 5,000 participants using the ASSURE wearable cardioverter defibrillator.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 3 years to measure the study's main outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05135403

ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)

Recruiting
Not specifiedAges 18+Observational
Kestra Medical Technologies, Inc.
~5,179 participants
Updated 2025-09-02 on ClinicalTrials.gov
What's tested:Defibrillation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall shock conversion rate
Measured over Up to 3 years
+1 more outcome measured
Sudden Cardiac Arrest
1 sites across 1 states
Washington1
  • Jeanne Poole, M.D. · PRINCIPAL_INVESTIGATOR · University of Washington

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patient prescribed the ASSURE wearable cardioverter defibrillator
Provided written informed consent to participate in the ASSURE Patient Registry
  • Overall shock conversion rateUp to 3 years

    Percent of spontaneous episodes of ventricular tachycardia/ventricular fibrillation (VT/VF) successfully converted with one or more shocks ≥ 89.0%

  • Inappropriate shocks per patient monthUp to 3 years

    Total inappropriate shocks/cumulative months of WCD use for all patients ≤ 0.0075